

Annette Rodriguez Khaled, Ph.D.

Contact Information

Office

Division of Cancer Research
Burnett School of Biomedical Sciences
College of Medicine
University of Central Florida
6900 Lake Nona Blvd, Orlando, FL 32827
(407) 266-7035
E-mail: annette.khaled@ucf.edu
Website: <https://med.ucf.edu/akhaled/>

Home

409 Moss View Circle
Orlando, FL 32825
(407) 517-9706
(786) 877-9419 (cell)

Education/Training

Post-doctoral training, Laboratory of Molecular Immunoregulation.....1998-2002
National Cancer Institute (NCI)-Frederick, Frederick, MD
Mentor: Scott Durum, PhD

Ph.D. in Molecular Genetics & Microbiology.....1992-1997
College of Medicine, University of Florida, Gainesville, FL
Dissertation title: "A Study of NFkB and Ikb Proteins in Murine Models of Autoimmunity" Mentor:
Joel Schifffenbauer, M.D.

M.S. in Microbiology.....1987-1991
School of Natural Sciences
California State University Long Beach, Long Beach, CA
Thesis Title: "Detection of polymorphic forms of the CD45RA exon in SLE patients and normal controls."
Mentor: Michael Liebling, M.D.

B.S. in Biological Sciences.....1978-1982
University of California, Irvine, CA.

Academic Appointments and Experience

Professor, tenured.....2017-Present
Burnett School of Biomedical Sciences
College of Medicine, University of Central Florida, Orlando, FL

Head, Division of Cancer Research.....2015-Present
Burnett School of Biomedical Sciences,
College of Medicine, University of Central Florida, Orlando, FL.

Associate Professor, tenured.....2009-2017
 Burnett School of Biomedical Sciences
 College of Medicine, University of Central Florida, Orlando, FL.
 Coordinator, Biomedical PhD Program.....2010-2015
 University of Central Florida, Orlando, FL

Course Coordinator, BSC 6432/6433.....2010-2015
 University of Central Florida, Orlando, FL

Assistant Professor.....2002-2009
 Burnett School of Biomedical Sciences

Postdoctoral fellow.....1997-2002
 National Cancer Institute, NIH, Frederick, MD.

Graduate fellow.....1992-1997
 Dept. of Molecular Genetics & Microbiology
 College of Medicine, University of Florida, Gainesville, FL.

Research associate.....1991-1992
 Research & Development, Diamedix Corporation, Miami, FL.

Research associate.....1986-1991
 Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA

Research technician.....1983-1986
 Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA

Teaching Experience

University of Central Florida Burnett School of Biomedical Sciences

IDS 7690 **Frontiers in Biomedical Sciences**.....2017-Present
 PCB 5235 **Molecular Immunology**.....2011-Present
 PCB 4026/5937 **Molecular Pharmacology**.....2008-2009
 BSC 6433 **Biomolecular Sciences II**.....2004-2016
 PCB 4280 **Molecular Immunology**.....2004-2016

University of Central Florida College of Medicine2010-2016
 BMS 6006 **Health and Disease**

NCI-Frederick, Frederick, MD

Supervisor for Student Intern Program (SIP).....2000-2002

University of Florida, Gainesville, FL

Teaching assistant for medical students.....1992-1997

California State University, Long Beach, Long Beach, CA.

Teaching assistant for undergraduate microbiology courses.....1991

Teaching Awards

University of Central Florida College of Medicine

Outstanding Graduate Educator Award, COM Faculty and Student Awards.....2015, 2020

Mentoring

Past Research Trainees (chair of thesis/dissertation committees)

Amy Grenier	M.S., Microbiology and Molecular Biology, UCF	2002-2006
Nuska Tschammer	Ph.D., UCF	2003-2007
Christina Kittipatarin	Ph.D., UCF	2004-2010
Mounir Chehtane	Ph.D., UCF	2007-2010
Ge Zhang	M.S. Biotechnology, UCF	2008-2011
Shannon Ruppert	Ph.D., UCF	2007-2012
Rebecca Boohaker	Ph.D., UCF	2007-2012
Vipra Dhir	M.S., Biotechnology, UCF	2011-2015
Rania Bassiouni	Ph.D., UCF	2010-2015
Ali Mozayan	MD, UCF (FIRE module student)	2015-2016
Ana Carr	Ph.D., UCF	2013-2017
Anne Showalter	Ph.D., UCF	2015-2020
Kristen Hosang	MD, UCF (FIRE module student)	2017-Present
Michael Leong	MD, UCF (FIRE module student)	2018-Present

Current Research Trainees (chair of thesis/dissertation committees)

Daniel Nierneberg	Ph,D, UCF	2015-Present
Heba Ghozlan	PhD, UCF	2017-Present
Amanda Cox	MD/Ph.D,UCF	2018-Present

Thesis/Dissertation Committees Membership (from the last eight years)

Meenakshi Balakrishnan	Ph.D., UCF (graduated)	2007-2010
Soumya Jaganathan	Ph.D., UCF (graduated)	2007-2010
Jixiang Xia	Ph.D., UCF (graduated)	2006-2011
Xiaolei Zhang	Ph.D., UCF (graduated)	2007-2011
Crystal Archer	M.S., UCF (graduated)	2008-2011
Priya Sadumar	M.S., UCF (graduated)	2008-2011
Pranav Garg	M.S., UCF (graduated)	2008-2011

Kristy Bradley	M.S. in Simulations (IST) (graduated)	2009-2011
Brian Scharen	Ph.D., UCF (graduated)	2009-2012
Tisha Choudhury	Ph.D., UCF (graduated)	2007-2013
Colleen Eade	Ph.D., UCF (graduated)	2007-2013
Alejandra Petrilli Guinart	Ph.D., UCF (graduated)	2008-2013
Melissa Wason	Ph.D., UCF (graduated)	2008-2013
Tianshu Li	Ph.D., UCF (graduated)	2010-2013
Jennifer Archer	Ph.D., UCF (graduated)	2010-2014
Bonnie Berry	Ph.D., UCF (graduated)	2010-2015
Brittany Pease	Ph.D., UCF (graduated)	2010-2015
Veethika Pandey	Ph.D., UCF (graduated)	2011-2015
Toya Albury	Ph.D., UCF (graduated)	2011-2015
Cassandra Dennys	Ph.D., UCF (graduated)	2011-2015
Orielyz Flores	Ph.D., UCF (Chemistry) (graduated)	2012-2015
Michael Riley	M.S., UCF (graduated)	2013-2015
Esha Sehanobish,	Ph.D., UCF (graduated)	2012-2016
Debarti Mukherjee	Ph.D., UCF (graduated)	2011-2016
Richard Ottman	Ph.D., UCF (graduated)	2012-2016
Sarah Gitto	Ph.D., UCF (graduated)	2013-2017
Nikki Allen	Ph.D., UCF (graduated)	2013-2017
Marisa Fuse	Ph.D., UCF (graduated)	2013-2017
Swaran Nandini	Ph.D., UCF	2013-2019
Alisha Colon	Ph.D., UCF	2013-2019
Candace Fox	Ph.D., UCF	2015-2019
Maria Cruz	Ph.D., UCF	2015-2020
Cheyenne Fedder	Ph.D., UCF	2016-Present
Kavya Ganapathy	Ph.D., UCF	2016-Present
Sai Preethi Nakkina	Ph.D., UCF	2018-Present
Dania Alqasrawi	Ph.D., UCF	2018-2020
Haley Hardin	MS, UCF	2018-Present
Minerva Ventolero	Ph.D., UCF	2018-Present
Caroline Finn	Ph.D., UCF	2018-Present
AnaMaria Alvarez	Ph.D., UCF	2019-Present

Master's of Science Capstone Students

Alexey Goloubev	2015
Sarah Ellis	2015
Morgan Muhlenkamp	2016
Erica Cipparone	2016
Alisa Grace	2017
Dang-Khoa Nguyen	2017
Dima Alshaibi	2018

Alexandra Ware	2020
Annsophia Mompont	2020
Jordan Lass	2020

Post-doctoral Trainees

Deepika Minhas, Ph.D.	2002-2004
Gun Lee, Ph.D.	2008-2009
Kathleen Nemec, Ph.D.	2007-2012, 2015
Rania Bassiouni, Ph.D.	2015-2016
Orielyz Flores, Ph.D.	2015-2019
Ana Carr, Ph.D.	2017-2020

Funding (grants, awards and philanthropy)

HERI Research Grant Program.....2019-2020
 Title: *Chaperonin-Containing TCP-1 In Lung Cancer Health Disparity*
 Role: PI
 Source: Florida HERI Program
 Amount: \$19,000

COM Interdivision Research Grant Program.....2019-2020
 Title: *Stealth Nanoparticles for Tumor Drug Delivery that Mimic Immune Cells*
 Role: PI with Dr. Kai McKinstry
 Source: College of Medicine
 Amount: \$40,000

NSTC Seed Award.....2019-2020
 Title: *Generating Nanoparticles with Improved Tumor Penetration*
 Role: PI with DR. Lei Zhai
 Source: UCF
 Amount; \$30,000

COM Competitive Research Grant Program.....2018-2019
 Title: *Detection of Circulating Tumor Cells Based on Chaperonin Levels*
 Role: PI
 Source: College of Medicine
 Amount: \$25,000

Breast Cancer Research Foundation (BCRF) grant.....2017-Present
 Title: *Inhibiting protein-folding activity for the treatment of metastatic breast cancer.*
 Role: PI
 Source: BCRF
 Amount: \$250,000/year

Hardee Family Foundation Pledge.....2018-2023
 Title: Hardee Family Foundation Cancer Research Fund
 Role: PI
 Source: Hardee Family Foundation
 Amount: \$50,000

The Cathy Engelman Cancer Research Collaborative Fund.....2017-2019
 Title: Project to purchase the CELLSEARCH system
 Role: PI
 Source: Catherine McCaw-Engelman and Family Cancer Research Collaborative Fund. Amount:
 \$197,000

Preeminent Postdoctoral Program (P3).....2017-2019
Role: PI
Source: University of Central Florida
Amount: \$63,000

Reach for the Stars Award.....2016-2019
(This award is given to faculty as recognition for highly successful research activity)
Source: University of Central Florida
Role: PI
Amount: \$10,000 annual research grant

Breast Cancer Research Foundation (BCRF) grant.....2015-2017
Title: *Development of a Cytoskeletal-Disrupting Approach for the Treatment of Metastatic Breast Cancer*
Role: PI **Source:** BCRF
Amount: \$250,000/year (additional \$145,833 awarded as interim funding for 3/1/16 - 9/30/16)

RO1EB019288 Grant.....2014-2018
Title: *A novel polymeric nanotechnology platform with imaging capabilities for targeted delivery of a therapeutic peptide*
Role: MPI (with Perez (contact))
Source: NIBIB, NIH
Amount: My average total costs \$142,274/year (total award ~\$1,239,000)

COM Competitive Research Grant Program.....2016-2017
Title: *Discovery of Novel Therapeutics that Target Cancer Stem Cells* **Role:**
 PI
Source: College of Medicine
Amount: \$15,000

COM Competitive Research Grant Program.....2014-2015
Title: *Evaluating Chaperonin-containing Tcomplex (CCT) as a biomarker for metastatic cancer*
Role: PI
Source: College of Medicine
Amount: \$20,000

COM Competitive Research Grant Program.....2014-2015
Title: *Targeting Therapeutic Agents to Breast Cancer using the Metabotropic Glutamate Receptor 1 (GRM-1)*
Role: PI
Source: College of Medicine
Amount: \$20,000

James and Esther King Award.....2012-2015
Title: *Generation of highly cytotoxic natural killer cells for cellular therapy of cancers using novel microparticle approach.*
Role: Co-PI/mentor (Copik: PI)
Source: Florida Department of Health
Amount: \$350,000

COM Competitive Research Grant Program.....2012-2013
Title: *Development of Murine Xenograft Models for the Testing of Anti-cancer Therapeutics*
Role: PI
Source: College of Medicine
Amount: \$20,000

Florida Breast Cancer Foundation (FBCF) award.....2012-2014
Title: *Targeting Cytotoxic Peptides to Tumor Vasculature to Treat Breast Cancer*
Role: PI **Source:** FBCF
Amount: \$100,000

Florida Hospital Gala Award.....2012-2013
Title: *Development of cancer immunotherapy: Methods for expansion and activation of immune cells with direct anti-tumor activity*
Role: Co-PI
Source: Florida Hospital
Amount: \$45,000

ARRA Supplement.....2009-2011
Role: PI
Source: NIGMS, NIH
Amount: \$241,774

R01GM083324 grant.....2008-2013
Title: *Identification of Regulatory Domains that Mediate the Membrane-binding of BAX*
Role: PI
Source: NIGMS, NIH
Amount: ~\$252,000/year (total award ~\$1,040,000)

R01CA109524 grant.....2007-2010
Title: *IL-7 and Lymphocyte Homeostasis: Life versus Death*
Role: PI
Source: NCI, NIH
Amount: ~\$195,000/year (total award ~ \$780,000)

Research Supplement to Promote Diversity in Health-Related Research.....2007-2010
Supplement to parent R01CA109524
Role: Mentor (PI: M. Chehtane, graduate student)
Source: NCI, NIH
Amount: \$43,000/year (total award \$172,000)

Florida Hospital Gala Award.....2006-2007
Title: *Alkaline pH Triggers the Apoptotic Activity of the Tumor Suppressor, BAX* **Role:**
PI
Source: Florida Hospital
Amount: \$20,000

F31 Minority Predoctoral Fellowship.....2005-2008
Role: Mentor (PI: C. Kittipatarin, graduate student)
Source: NIGMS, NIH
Amount: \$92,526

K22CA097984 grant.....2003-2006
Title: *Role of Bax and pH in Death by Cytokine Withdrawal*
Role: PI
Source: NCI, NIH
Amount: \$175,000/year (total award ~\$525,000)

F31AI009545 award.....1994-1997
Title: MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
Source: NIGMS, NIH
Amount: \$48,264

Patents and Licensing Agreements

Issued

- (1) METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE. Patent no. US 10,159,706 B2. Original date of patent: May, 26, 2015, re-issued 12/25/18.
- (2) COMPOSITIONS COMPRISING IL-7 RECEPTOR LIGANDS. Patent no. US9,266,937 B2. Date of patent: Feb. 23, 2016
- (3) COMPOSITIONS AND METHODS FOR PURIFYING BAX. Patent no. US 9,403,888. Date of patent: August 2, 2016

Applied

- (1) CHAPERONIN CONTAINING TCP-1 (CCT) INHIBITION FOR TREATING CANCER for which an application for a Provisional Patent was filed on Dec. 7, 2015. Converted on Dec. 7, 2016.
- (2) METHODS AND COMPOSITIONS FOR THERANOSTIC NANOPARTICLES TECHNICAL FIELD for which an application for U.S. Letters Patent was filed on April 28, 2015. Converted on April 28, 2016.
- (3) METHODS AND COMPOSITIONS COMPRISING A CT20 PEPTIDE for which an application for U.S. Letters Patent was filed on July 18, 2014 as Serial No. 62/026,564 and an international application filed July 9, 2015. Converted on July 9, 2016.

Licensing Agreements

A licensing agreement for patents (above) was signed with SEVA Therapeutics, Inc. in 2016

Research Awards, Honors and Recognition

University of Central Florida

- Orlando Medical News.....Jun 18, 2020
<https://www.orlandomedicalnews.com/article/3562/ucf-researchers-start-projects-to-fight-the-pandemic>
- UCF Today.....Feb. 5th, 2020
<https://www.ucf.edu/news/ucf-researcher-finds-new-signal-that-your-breast-cancer-is-growing/>
- Relay for Life on CW18 WKCF.....Mar. 22, 2019
<https://www.facebook.com/ourMedicalSchool/photos/dr-annette-khaled-and-christopher-alegria-cancer-survivor-and-ucf-student-talk-a/10157340671072859/>
- COM News.....Sept. 16, 2019
<https://med.ucf.edu/news/excitement-building-for-cure-bowl-2019/>
- UCF Today.....Dec. 14th, 2018
<https://www.ucf.edu/news/bowl-game-supports-ucf-breast-cancer-research/>
- CureBowl 2018.....Dec. 12, 2018
https://www.youtube.com/watch?v=vZqO_3lPUgE
- Interview for WKMG-TV (channel 6) show "The Weekly".....Dec. 9, 2018
- Innovate Orlando Interview (book chapter on UCF).....Nov. 29, 2018

American Medicine Today interview (Bloomberg TV).....Nov. 15, 2018
Ivanhoe Broadcast New.....Oct. 15, 2018
<https://www.ivanhoe.com/medical-breakthroughs/cellsearch-counts-cancer-cells/>
UpMatters Interview.....Oct. 10, 2018
<https://www.upmatters.com/news/healthwatch/working-to-stop-the-spread-of-cancer/1515028628>
News, Announcements at UCF.....June 28, 2018
<https://today.ucf.edu/med-school-can-see-count-cancer-cells-blood-thanks-patients-family/>
Ivanhoe News.....Jan. 24th, 2018
<https://www.ivanhoe.com/medical-breakthroughs/annette-khaled-cancer-assassin/>
UCF Today.....Dec 15, 21, 2017
<https://today.ucf.edu/autonation-cure-bowl-raises-3-3-million-breast-cancer-research/>
<https://today.ucf.edu/doctor-mommy-earns-ph-d-today-stays-ucf-continue-finding-cancer-cure/>
Ivanhoe Broadcasting TV interview..... Nov. 5, 2017
Luminary Award.....Oct. 18, 2017
<https://today.ucf.edu/ucf-honors-luminary-leaders-changing-world/>
Lifetime TV interview (videos used to promote BCRF funded researchers).....Oct. 5, 2017
<https://www.dropbox.com/sh/oegndcjwfk16bpd/AABt1IPbUqCtjeip5WQeyTC0a?dl=0>
Inducted into the UCF Scroll and Quill Society.....April 13, 2017
UCF Today.....Dec.19, 2016
<http://today.ucf.edu/cure-bowl-2016-raises-1-15-million-breast-cancer-including-250000-ucf/>
<http://today.ucf.edu/knights-dedicate-cure-bowl-game-battling-cancer/>
YouTube.....Dec. 19, 2016
<https://www.youtube.com/watch?v=RF9PhFN437I&feature=youtu.be>
Live TV interview with Jazmin Bailey on WESH (Channel 2).....Dec. 16, 2016
TV interview for Community Spotlight with Greg Warmuth (Channel 9).....aired Dec. 11, 2016
<http://www.wftv.com/news/centralfloridaspotlight>
College of Medicine News.....Nov. 17, 2016
<https://med.ucf.edu/news/dr-khaled-autonation-cure-bowl-honored-at-ucf-tulane-game/>
CureBowl 2015 Recap.....October 2016
<https://vimeo.com/182449157/244ed0e647>
NSM Today (with Alan Gooch).....Oct. 20, 2016
http://www.nicholsonstudentmedia.com/sports/ucf-alumnus-alan-gooch-raises-awareness-withcure-bowl/article_9f1e113a-96eb-11e6-9fcf-afe322fe0fb4.html
The Orlando Business Journal.....Oct. 16, 2016
<http://www.bizjournals.com/orlando/news/2016/10/06/how-3-local-doctors-are-making-greatstrides-in.html>
Miami Herald.....Sept. 23, 2016
<http://www.miamiherald.com/living/health-fitness/article103607097.html>
EurekaAlert.....Aug. 24, 2016
https://www.eurekaalert.org/pub_releases/2016-08/uocf-utf082416.php
College of Medicine News.....Aug. 8, 2016
<https://med.ucf.edu/news/ucf-technology-for-killing-metastatic-breast-cancer-cells-discoveredlicensed/>

UCF Today.....Apr. 6, 2016
<https://med.ucf.edu/news/2016/04/burnett-faculty-undergrad-honored-at-founders-day/>
 UCF Today.....Jan. 11, 2016
<https://med.ucf.edu/news/2016/01/bowl-game-fever-helps-cancer-research/>
 UCF Today.....Dec. 21, 2015
<https://med.ucf.edu/news/2015/12/cure-bowl-donates-150000-to-breast-cancer-research/>
 Research highlighted on Clear Channel Digital Billboards in the Orlando area.....Dec. 2015
 Live TV interview on WESH (Channel 2) Dec. 17, 2015
 Radio Interview on WMFE for Growing Bolder Radio show.....Dec. 6, 2015
 The Orlando Business Journal.....Oct. 9, 2015
<http://www.bizjournals.com/orlando/print-edition/2015/10/09/how-i-helped-bring-1-6m-in-grantmoney-to-ucf-for.html>,
 Research highlighted on Fox News and Orlando Sentinel.....2014
 Research Incentive Award (RIA) (\$5000/year).....2013
 Research highlighted in UCF News and Information and presented by WMFE.....2008

American Association of Immunologists (AAI)

AAI Laboratory Award.....2015
 Mid-career Investigator Travel Award.....2011
 Minority Scientist Travel Award.....2005
 Minority Scientist Travel Award.....2003

International Cytokine and Interferon Society (ICIS)

Young investigator award (2nd place)..... 2007
 Young investigator award (1st place).....2004
 Postdoctoral investigator travel award.....2002
 Postdoctoral investigator travel award.....1999

National Institutes of Health (NIH)

CURE Lifetime Achievement Honoree, Celebrating 21 years of the CURE Program.....2017
 Star of Excellence (1st place poster award), NCI Professional Development Workshop.....2007
 “Best Cytokine Paper Published by an NIH Scientist” Award.....2002
 Poster presentation award, Postdoctoral, Fort Detrick Spring Research Festival.....2002
 Fellows Award for Research Excellence (FARE)2000, 2001, 2002
 Book Award for Meritorious abstract submission, Fellows' Symposium..... 2001
 Merit Bonus, exceptional stipend increase.....2000-2002
 Poster presentation award, Postdoctoral, Fort Detrick Spring Research Festival.....1999

American Society for Cell Biology (ASCB)

Minority Scientist Travel Award.....2006

University of Florida

Poster presentation award, Graduate Student Forum.....	1995
Paper presentation award, Graduate Student Forum.....	1996
Paper presentation award, Graduate Student Forum.....	1997

Peer-reviewed Publications (total 58 published - 3 pending)

Published since joining UCF (*Khaled lab student or post-doc researchers)

1. Cox A, A Martini, D. Decker, L Barr, C Alemeny, R Moroose, AS Khaled and **AR Khaled**. 2020. Detection of Circulating Tumor Cells from the Blood of Metastatic Breast Cancer Patients using Chaperonin- Containing TCP1 Subunit 2 (CCT2). *In preparation*.
2. Ghozlan H, A Showalter, P Gopalan, AS Khaled and **AR Khaled**. 2020. Breast Cancer Spheroid Formation is Enhanced By Expression of Chaperonin- Containing TCP1 Subunit 2 (CCT2). *In preparation*.
3. Nierenberg D, Flores O, Fox D, Sip YYL, Finn C, Ghozlen H, Cox A, McKinstry KK, Zhai Land, Khaled AR. 2020. Protein corona formation in the modulation of transendothelial transport and the tumor biodistribution of polymeric nanoparticles. Submitted to *Int J Nano*.
4. Showalter AE, AC Martini, D Nierenberg, K Hosang, NA Fahmi, P Gopalan, AS Khaled, W Zhang, and **AR Khaled**. 2020. Investigating Chaperonin-Containing TCP-1 subunit 2 as an essential component of the chaperonin complex for tumorigenesis. *Scientific Reports*. 10, Article number:798 (2020).
5. Doshi M, O Flores-Fernandez*, P Deme, D Nierenberg*, **AR Khaled**, and S Parthasarathy. 2019. Cypate and cypate-glucosamine as near infrared (NIR) fluorescent probes for imaging. *Mol Pharm*. 95(5):475-489.
6. Xin LI; Naser SA, **Khaled A**, Hu H, Li X. 2018. When old metagenomic data meet newly sequenced genomes, a case study. *PLoS One*. 13(6):e0198773
7. Nierenberg D*, O Flores* and **AR Khaled**. 2018. Formation of a Protein Corona Influences the Biological Identity of Nanomaterials. *Reports of Practical Oncology and Radiotherapy*. Invited Review. 23(4):300-308.
8. Mozayan A* and **AR Khaled**. 2018. Elucidation of Therapeutic Peptide Binding Partners from Isolated Mitochondria. *Cureus* 10(6): e2898.
9. Carr A*, AS Khaled, R Bassiouni*, O Flores*, D Nierenberg*, H Bhatti, P Vishnubhotla, JM Perez, S Santra, and **AR Khaled**. 2017. Targeting Chaperonin Containing TCP1 (CCT) as a Molecular Therapeutic for Small Cell Lung Cancer. *Oncotarget*. 8(66):110273-88.
10. Showalter A*, A Limaye*, JL Oyer, R Igarashi, C Kittipatarin*, AJ Copik, and **AR Khaled**. 2017. Cytokines in Immunogenic Cell Death: Applications for Cancer Immunotherapy. *Cytokine*. 97:123-132.
11. Flores O*, S Santra, C Kaittanis, R Bassiouni*, AS Khaled, **AR Khaled**, J Grimm, and JM Perez. 2017. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer. *Theranostics*. 7(9):2477-2494.
12. Bassiouni R*, K Nemec*, A Iketani, O Flores*, A Showalter*, RW Sprung, C Kaittanis, P Vishnubhotla, AS Khaled, JM Perez, **AR Khaled**. 2016. Chaperonin containing-TCP-1 protein

level in breast cancer cells predicts therapeutic application of a cytotoxic peptide. *Clin Cancer Res.* 22(17):4366-79

13. Lee MW, R Bassiouni*, A Iketani, JM Perez and **AR Khaled**. 2014. The CT20 peptide: More than a piece of Bax. *Cancer Cell and Microenvironment.* 1:e266

14. Lee MW, R Bassiouni*, NA Sparrow*, A Iketani, RJ Boohaker*, C Moskowitz*, P Vishnubhotla, AS Khaled, J Oyer, A Copik, C Fernandez-Valle, JM Perez and **AR Khaled**. 2014. The CT20 Peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption. *Cell Death and Disease.* 22:5 e1249

15. Garg P*, KN Nemec, **AR Khaled**, SA Tatulian. 2013. Transmembrane pore formation by the carboxyl terminus of Bax protein. *Biochim Biophys Acta.* 1828(2):732-42

16. Tatulian SA, P Garg*, KN Nemec, **AR Khaled**. 2012. Molecular basis for membrane pore formation by Bax protein carboxyl terminus. *Biochemistry* 51(46):9406-19

17. Ruppert SM*, W Li, G Zhang*, AL Carlson, A Limaye*, SK Durum, **AR Khaled**. 2012. The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes. *Biochim Biophys Acta.* 1823(10):1877-93.

18. Boohaker RJ*, G Zhang*, MW Lee, KN Nemec, S Santra, JM Perez, **AR Khaled**. 2012. Rational development of a cytotoxic peptide to trigger cell death. *Mol Pharm.* 9(7):2080–93

19. Boohaker RJ*, MW Lee, P Vishnubhotla, JM Perez, **AR Khaled**. 2012. The use of therapeutic peptides to target and to kill cancer cells. *Curr Med Chem* 1;19(22):3794-804.

20. Altomare DA, **AR Khaled**. 2012. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. *Curr Med Chem.*1;19(22):3748-62.

21. Ruppert SM*, M Chehtane*, G Zhang*, H Hu, X Li, **AR Khaled**. 2012. JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction. *PLoS One.* 2012;7(2):e32262. Epub 2012 Feb 23.

22. Boohaker RJ*, G Zhang*, A Loosely, KN Nemec* and **AR Khaled**. 2011. BAX supports the mitochondrial network, promoting bioenergetics in Non-Apoptotic Cells. *AJP: Cell Physiology.* 300(6):C1466-1478.

23. Kittipatarin C*, W Li, SK Durum, **AR Khaled**. 2010. Cdc25A-driven proliferation regulates CD62L levels and lymphocyte movement in response to interleukin-7. *Exp Hematol.* 38(12):1143-56]

24. Kittipatarin C*, N Tschammer* and **AR Khaled**. 2010. The Activity of LCK upon STAT5 can differentially modulate Interleukin-7 signaling in CD4 and CD8 T cells. *Immunol Letts.* 131(2):170-81.

25. Chehtane M* and **AR Khaled**. 2010. Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the Hexokinase II gene expression. *AJP: Cell Physiol* 298(6):C1560-71.

26. Kittipatarin C* and **AR Khaled**. 2009. Ex vivo expansion of memory CD8 T-cells from lymph nodes or spleen through in vitro culture with interleukin-7. *J. Immunol Methods.* 15;344(1):45-57.

27. Nemec KN* and **AR Khaled**. 2008. Therapeutic Modulation of Apoptosis: Targeting the BCL2 family at the interface of the mitochondrial membrane. *Yonsei Med J.* 49(5):689-97.

28. Grenier AD*, K Abu-ihweij*, G Zhang*, S Ruppert*, RJ Boohaker*, E Slepko, K Pridemore, JJ Ren, L Fliegel, and **AR Khaled**. 2008. Apoptosis-induced alkalinization by the

Na⁺/H⁺ exchanger isoforms 1 is mediated through phosphorylation of amino acids Ser726 and Ser729. *Am J Physiol Cell Physiol.* 295(4):C883-96.

29. Kaur N, J Delcros, M Chehtane*, N Tschammer*, **A Khaled** and O Phanstiel. 2008. A comparison of Chloroambucil- and Xylene-containing polyamines leads to improved ligands for accessing the polyamine transporter. *J. Med. Chem.* 51(5):1393-401.

30. Kittipatarin C* and **AR Khaled**. 2007. Interlinking Interleukin-7. *Cytokine* 39:75-83.

31. Xie S, P Cheng, G Liu, Y Ma, J Zhao, M Chehtane*, **AR Khaled**, O Phantstiel, and C Wang. 2007. Synthesis and bioevaluation of the N-(Arylalkyl)-homospermidine conjugates. *BMCL* 17(16):4471-5.

32. Iacovelli J, J Lopera, M Bott, E Baldwin, **A Khaled**, N Uddin, and C Fernandez-Valle. 2007. Serum and forskolin cooperate to promote G1 progression in Schwann cells by differentially regulating cyclin D1, cyclin E1, and p27 expression. *GLIA* 55(16):1638-47..

33. Kittipatarin C*, W.Q. Li, D Bulavin, SK Durum and **A.R. Khaled**. 2006. Cell Cycling Through Cdc25A: Transducer of Cytokine Proliferative Signals. *Cell Cycle.* 5:907-12.

34. Li WQ, Q Jiang, E Aleem, P Kaldis, **AR Khaled**, SK Durum. 2006. IL-7 promotes T cell proliferation through destabilization of p27Kip1. *J Exp Med.* 203(3):573-82.

35. Kotha A, M Sekharam, L Cilenti, K Siddiquee, **A Khaled**, AS Zervos, B Carter, J Turkson and R Jove. 2006. Resveratrol inhibits Src and Stat3 and induces the apoptosis of malignant cells containing activated Stat3. *Mol Can Ther.* (3):621-9.

36. **Khaled A**, S Guo, F Li, P Guo. 2005. Controllable Self-Assembly of Nanoparticles for Specific Delivery of Multiple Therapeutic Molecules to Cancer Cells Using RNA Nanotechnology. *Nano Lett.* 14;5(9):1797-1808

37. Jiang Q, WQ Li, FB Aiello, R Mazzucchelli, B Asefa, **AR Khaled**, SK Durum. 2005. Cell biology of IL-7, a key lymphotrophin. *Cytokine Growth Factor Rev.* 16(4-5):513-33.

38. **Khaled AR**, DV Bulavin, C Kittipatarin*, WQ Li, KM. Alvarez, K Kim, HA Young, AJ Fornace, and SK Durum. 2005. Cytokine-driven cell cycling is mediated through Cdc25A. *J Cell Biology* 169[5]:755-63.

39. Jiang Q, WQ Li, RR Hofmeister, HA Young, DR Hodge, JR Keller, **AR Khaled**, SK Durum. 2004. Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. *Mol Cell Biol.* 24(14):6501-13.

40. Ashktorab H, S Frank, **AR Khaled**, S Durum, B Kifle, and DT Smoot. 2004. Bax translocation and mitochondrial fragmentation induced by H. pylori. *Gut* 53:805-13.

41. Li WQ, Q Jiang, **AR Khaled**, JR Keller, and SK Durum. 2004. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. *J Biol Chem.* 279(28):29160-6

42. Jiang Q, N Benbernou, O Chertov, **AR Khaled**, J Wooters and SK Durum. 2004. IL-7 induces tyrosine phosphorylation of clathrin heavy chain. *Cell Signal* 16:281-6.

43. **Khaled AR** and SK Durum. 2003. Death and Baxes: mechanisms of lymphotropic cytokines. *Immunol. Rev.* 193(1) :48-57.

44. Kim K, **AR Khaled**, D Reynolds, HA Young, CK Lee, and SK Durum. 2003. Characterization of an interleukin-7-dependent thymic cell line derived from a p53^{-/-} mouse. *J Immunol. Methods* 274:177-184.

Published during post-doctoral training from 1997-2002

1. **Khaled AR**, WQ Li, J Huang, TJ Terry, AS Khaled, CL Mackall, K Muegge and SK Durum. 2002. Bax deficiency partially corrects IL-7 receptor-alpha deficiency. *Immunity* 17:561-73.
2. **Khaled AR** and SK Durum. 2002. Lymphocyte. Death in the absence of cytokine signaling controls lymphoid homeostasis. *Nature Rev. Immunol.* 2:817:830.
3. **Khaled, AR** and SK Durum. 2002. The role of cytokines in lymphocyte homeostasis. *Biotechniques*, Oct. 2002 Supplement: 40-5.
4. Szocinski JL, **AR Khaled**, J Hixon, D Halverson, S Funakoshi, WC Fanslow, A Boyd, DD Taub, SK Durum, CB Siegall, DL Longo, and WJ Murphy. 2002. Activation induced cell death of aggressive histology lymphomas by CD40 stimulation: Bax. *Blood* 100:217-223.
5. **Khaled AR** and SK Durum. 2001. From cytosol to mitochondria: the Bax translocation story. *J. Biochem. Mol. Biol.* 34(5):391-394.
6. **Khaled AR**, AN Moor, L Aiqun, K Kim, DK Ferris, RJ Fisher, L Fliegel, and SK Durum. 2001. Trophic factor withdrawal: p38 MAP kinase activates NHE1 inducing intracellular alkalinization. *Mol. Cell. Biol.* 21(22):7545-7557.
7. **Khaled AR**, DA Reynolds, HA Young, CB Thompson, K Muegge and SK Durum. 2001. IL-3 withdrawal induces an increase in mitochondrial membrane potential unrelated to the Bcl-2 family: Roles of intracellular pH, ADP transport and F0F1-ATPase. *JBC* 276(9): 6453-62.
8. Welniak LA, **AR Khaled**, M Anver, D Reynolds, K Komschlies, R Wilttrout, H Young, R Blazar, S Durum, and WJ Murphy. 2001. Non-Immune action of interleukin-7: Intestinal crypt cells of interleukin-receptor deficient mice are highly sensitive to g-irradiation damage. *J. Immunol.* 166: 2923-2928.
9. **Khaled AR**, K Kim, R Hofmeister, K Muegge, and SK Durum. 1999. Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. *Proc.Natl. Acad. Sci., USA.* 96(25): 14476-14478.
10. Hofmeister R, **AR Khaled**, N Benbernou, E Rajnavolgyi, K Muegge, and SK Durum. 1999. IL-7. Physiological roles and mechanisms of action. *Cyto. Growth Factor Rev.* 10:41-60.

Published as a pre-doctoral student from 1992-1997

1. **Khaled AR**, E Butfiloski, B Villas, E Sobel and J Schiffenbauer. 1999. Aberrant expression of the NF-kB and Ikb proteins in B cells from motheaten viable mice. *Autoimmunity* 30:115-128.
2. **Khaled AR**, E Butfiloski, E Sobel and J Schiffenbauer. 1998. Functional consequences of the SHP1 defect in motheaten viable mice: Role of NF-kB. *Cell. Immunol.* 185:49-58.
3. **Khaled AR**, E Butfiloski, E Sobel and J Schiffenbauer. 1998. Use of phosphorothioate-modified deoxyoligonucleotides to inhibit NF-kB expression and lymphocyte function. *Clin. Immunol. Immunopathol.* 86:170-179.
4. **Khaled AR**, L Soares, E Butfiloski, I Stekman, E Sobel and J Schiffenbauer. 1997. Inhibition of p50 subunit of NF-kB by antisense oligodeoxynucleotides reduces NF-kB expression and immunoglobulin synthesis in murine B cells. *Clin. Immunol. Immunopathol.* 83:254-263.

Published as a research associate/technician 1987-1992

1. Liebling MR, J Nishio, **A Rodriguez**, LH Siegel, T Jin, and J Louie. 1993. The polymerase chain reaction for the detection of *Borrelia burgdorferi* in human body fluids. *Arth. Rheum.* 36:665-675.

2. Keller MA, L Gendreau-Reid, DC Heiner, **A Rodriguez**, and JA Short. 1988. IgG4 in human colostrum and human milk: continued local production or selective transport from serum. *Acta. Paediatr. Scand.* 77:24-29.
3. Keller MA, **A.L.Rod(g)riguez**, S Alvarez, NC Wheeler, and D Reisinger. 1987. Transfer of tuberculin immunity from mother to infant. *Pediatr. Res.* 22:277-281.

Fictional publications.

Rodriguez A. "Broken Vows". In Renunciates of Darkover, ed. Marion Zimmer Bradley, Daw Books, New York, N.Y. 1991

Abstracts (total 51)

*Published since joining UCF (*Khaled lab student or post-doc researchers)*

1. Flores O*, D Nierneberg*, A Carr*, R Bassiouni*, A Limaye*, S Santra, C Kaittanis, JM Perez, **AR Khaled**. Peptide power: A PSMA-targeted CT20 nanoparticle to fight prostate cancer. 2017. [abstract]. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; Washington DC. *Cancer Research* 77(13 Supplement):3241-3241
2. Carr A*, AS Khaled, R Bassiouni*, **AR Khaled**. CT20p as a therapeutic for lung cancer with elevated chaperoning containing TCP1 (CCT) expression levels. [abstract]. 2017. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; Washinbgton DC. *Cancer Research* 77(13 Supplement):4895-4895.
3. Vishnubhotla, P; Carr, AC*; Khaled, A; Bassiouni, R*; **Khaled, AR**. CT20p as a therapeutic for lung cancer with elevated chaperonin containing TCP1 (CCT) expression levels. 2017. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO, Chicago, IL. *J Clin Oncol* 35(15):e23163.
4. **Khaled AR**, Amr S. Khaled, Rania Bassiouni*, Priya Vishnubhotla. Chaperonin containing-TCP1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; *Cancer Res* 2016;76(14 Suppl):Abstract nr 4121.
5. Lee, MW; Moskowitz, C; Perez, JM; **Khaled, A**. CT20p induced autophagy in breast cancer cells can be overcome by co-treatment with 3-methyladenine to maximize cell death. 2016 In: Experimental Biology Meeting, San Diego, CA. *FASEB J* 30(supplement 1):747.3
6. **Khaled AR**, Limaye A*, Bassiouni R*, Showalter A*, Oyer J, Pandey V, Igarashi R, Altomare DA, Copik AJ. Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy. [abstract]. In: Proceedings of the 38 Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res* 2016;76(4 Suppl):Abstract nr P4-04-12.
7. Vishnubhotla P, **Khaled AR**, Khaled AS, Perez JM, Bassiouni R*, Flores O*, Nierenberg D*. The dynamic duo: A breast cancer-targeting nanoparticle loaded with a cytotoxic peptide as a treatment for metastatic disease. [abstract]. In: Proceedings of the Thirty-Eighth Annual

- CTRCAACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res* 2016;76(4 Suppl):Abstract nr P5-03-02.
8. Khaled AS, Vishnubhotla P, **Khaled AR**, Bassiouni R*. Cutting the ties that bind: Targeting chaperonin-containing T-complex (CCT) for therapeutic intervention in the treatment of advanced stage breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRCAACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res* 2016;76(4 Suppl):Abstract nr P5-04-04.
 9. **Khaled A**, R Bassiouni*, A Limaye*, J Oyer, R Igarashi, O Flores*, J Perez and A Copik. Use of a cytotoxic peptide as an immunotherapeutic agent in the treatment of metastatic breast cancer 2015. *J. Immunol* 94 (1):214.14
 10. P Vishnubhotla, A Khaled, R Bassiouni*, O Flores*, JM Perez, **AR Khaled**. Chaperonincontaining T-complex (CCT) is a novel target for treatment of metastatic breast cancer. 2015. *J Clin Oncol* 33(5):e13530.
 11. Limaye A*, R Bassiouni*, J Oyer, RW Igarashi, O Flores*, JM Perez, A Copik, and **AR Khaled**. Use of a cytotoxic peptide that induces immunogenic cell death to engage innate immunity in the treatment of metastatic breast cancer. 2014. *Cancer Imm Res* 3:A47
 12. Limaye A*, A Iketani, R Boohaker*, J Oyer, K Nemec, M Solh, A Copik, and **AR Khaled**. IL7tv, a Modified Interleukin-7 protein, is a potent agent for immune reconstitution. 2013. *Cytokine* 63(2):282.
 13. Vishnubhotla P, RJ Boohaker*, MW Lee, KN Nemec*, A Khaled, S Santra, GM Perez, JM Perez, **AR Khaled**. Preclinical testing using a novel CT20p peptide-nanoparticle combination in breast cancer. 2013 *J Clin Oncol* 31(15):3085
 14. Vishnubhotla P, RJ Boohaker*, MW Lee, KN Nemec*, A Khaled, S Santra, GM Perez, JM Perez, **AR Khaled**. Preclinical testing using a novel CT20p peptide-nanoparticle combination in breast cancer. 2013. *Cancer Research* 73(supplement 24):P6-04-13.
 15. **Khaled, A**; Boohaker, R*; Finch, C; Tafur, S. Structural insights into the dynamic functionality of Bax through molecular dynamics simulations. 2013 *Cancer Res* 73(8):5138.
 16. Boohaker, R*; Zhang, G*; Nemec, K*; **Khaled, AR**. Development of a cytotoxic peptide based on the C-terminal domain of Bax. 2012. *Cancer Res.* 72(8):2010
 17. Tatulian, SA; Garg, P*; Nemec, KN*; **Khaled, AR**. Molecular Basis for Membrane Pore Formation by Bax Protein Carboxyl Terminus. 2012. *Biophysical J* 102(3):93A (Supplement 1)
 18. Garg P*, SA Tatulian, **AR Khaled**, KN Nemec*. Biophysical Characterization of Peptide Membrane Interactions and Membrane Permeabilization. 2011. *Biophysical J* 100[3]:40.
 19. Kittipatarin C*, N Tschammer* and **AR Khaled**. The Interaction of LCK and the CD4 Coreceptor alters the dose response of T-cells to interleukin-7. 2010. *Cytokine* 52[1-2]:14.
 20. Boohaker RJ*, G Zhang*, A Loosley, K Nemec*, **AR Khaled**. Compartmentalization of BCL2 Family proteins mediated by organelle lipid membranes. 2010 *Biophysical J* 98(3):379A.
 21. Nemec KN*, RJ Boohaker*, **AR Khaled**. Biophysical Insights into Bax oligomerization and membrane insertion. 2010 *Biophysical J* 98(3):464A
 22. Chehtane M* and **AR Khaled**. Interleukin-7 controls glucose uptake in T-lymphocytes by regulating hexokinase II gene expression. 2008. *Cytokine* 43[3]:288.
 23. Tschammer N*, TL Selby, **AR Khaled**. The membrane-binding activity of the apoptotic protein, BAX, is regulated through novel intermolecular interactions. 2007. *Cytokine* 39[1]:42-3.

24. Kittipatarin C*, **AR Khaled**. Interleukin-7 Drives the Homeostatic Proliferation of T-cells through the Activity of Cdc25A. 2007. *Cytokine* 39[1]:21.
25. **Khaled AR**, C Kittipatarin*, D Bulavin, WQ Li, K Kim, H Young, A Fornace, SK Durum. Cytokine-driven cell cycling is mediated through Cdc25A. 2005. *FASEB J* 19 (5):A1515.
26. N Tschammer*, PX Guo and **AR Khaled**. Use of the bacteriophage phi29 packaging RNA as nanovehicle for targeted delivery of therapeutic RNAs to CD4 T cells. 2005. *FASEB J* 19 (5):A1405.
27. **Khaled A**, A Grenier*, M Alvarez, D Bulavin, WQ Li, K Kim, AJ Fornace and S.K. Durum. G1 arrest follows loss of cytokine signaling through degradation of Cdc25A, mediated by p38 MAPK. 2004. *Nature Biotech. Short Report* 15:107.
28. **Khaled A**, WQ Li, and SK Durum. Death in the absence of cytokine signaling: Lessons learned from BAX/IL-7 receptor double deficient mice. 2003. *FASEB* 17[7]: C247.
29. Li WQ, Q Jiang, **A Khaled** and S Durum. Interleukin (IL)-7 activates PI3 kinase pathway and inactivates Bad both of which are associated with cell survival. 2003. *FASEB* 17[7]: C294.

Published during post-doctoral training from 1997-2002

1. **Khaled AR** and SK Durum. Death in the absence of trophic factor signaling: Lessons learned from Bax/IL-7 receptor deficient mice. 2002. *J. Interf. Cyto. Res.* 22: S-67-68.
2. Li, WQ, **AR Khaled**, and SK Durum. Interleukin-7 (IL)-7 induces AKT activation and Bad phosphorylation which are associated with T cell survival and proliferation. 2002. *J. Interfer. Cyto. Res.* 22 (Suppl 1):S-106.
3. **Khaled AR** and SK Durum. Loss of the trophic factor signaling during thymocyte development: on the pathway to death through intracellular alkalinization and Bax activation. 2002. *FASEB* 16 [4]: A341.
4. Durum SK, K Muegge, and **AR Khaled**. Bax deletion restores thymocyte development in IL-7R alpha deficient mice. 2001. *J. Leukocyte Biol.* 34 Suppl. S 2001.
5. **Khaled AR**, K Kim, K Muegge, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway: p38 MAPK activates NHE1 causing intracellular alkalinization, a novel step in apoptosis. 2001. *FASEB J.* 15 [5]: A1046.
6. Kim K, **AR Khaled**, K Muegge, and SK Durum. Characterization of an IL-7 dependent thymocyte cell line: D1. 2001. *FASEB J.* 15 [5]: A1194.
7. **Khaled AR**, K Kim, K Muegge, C Thompson, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway. 2001. *Nature Biotechnology, Short Reports* 12:93
8. **Khaled AR**, K Kim, K Muegge, C Thompson, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway. 2001. *The Scientific World Journal* 1(1Suppl 3):93.
9. **Khaled AR**, K Kim, K Muegge, and SK Durum. Trophic factor withdrawal induces a novel pathway: p38 MAPK activates NHE1 resulting in intracellular alkalinization, an early step in apoptosis. 2000. *Eur. Cytokine Netw.* 11: 206.
10. **Khaled AR**, K Kim, K Muegge, and SK Durum. 2000. IL-7 withdrawal induces a rise in intracellular pH through the NHE causing Bax translocation and a transient mitochondrial hyperpolarization. 2000. *FASEB J.* 14 (6): A1090.

11. **Khaled AR**, K Kim, K Muegge, and SK Durum. IL-7 withdrawal induces a rapid rise in intracellular pH causing: A) Bax translocation to mitochondria and B) Transient mitochondrial hyperpolarization. 1999. *Cytokine* 11(11): 975.
12. **Khaled AR**, K Kim, K Muegge, and SK Durum. The trophic action of IL-7: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. 1999. *Cold Spring Harbor Symposia Quant. Biology*, 64:93.
13. **Khaled AR**, K Kim, D Reynolds, HA Young, R Youle, K Muegge, and SK Durum. IL-7 Induces Transcription of bcl-2 and bcl-XL and prevents mitochondrial translocation of Bax. 1999. *FASEB J.* 13 (5): A981.
14. Welniak L.A, **A Khaled**, M Anver, D Reynolds, K Komschlies, R Wiltout, H Young, BR Blazer, S Durum, and WJ Murphy. Non-immune action of interleukin-7: Intestinal crypt cells of IL-7R deficient mice are highly sensitive to g-radiation damage. 1999. *FASEB J.* 13(5): A653.

Published as a pre-doctoral student from 1992-1997

1. **Khaled A**, E Butfiloski, E Sobel, and J Schiffenbauer.. Motheaten viable mice (mev) have defects in NF-kB and IkB protein expression not found in BXSB mice. 1997. AAAAI/AAI/CIS Joint Meeting. San Francisco, CA.
2. **Khaled A**, L Soares, E Butfiloski, I Stekman, E Sobel, and J Schiffenbauer.. Inhibition of the p50 subunit of NF-kB by antisense oligodeoxynucleotides reduces NF-kB expression and Ig synthesis in murine B cells. 1996. *FASEB J.* 10 (6):398.
3. **Khaled A**, E Butfiloski, E Sobel, and J Schiffenbauer. Aberrant expression of the NF-kB and IkB proteins in motheaten viable mice has the potential to cause immune dysfunction. 1996. *Arth. Rheum.* 39(9):S29.
4. Schiffenbauer J, **A Rodriguez**, and E Butfiloski. Aberrant expression of NF-kB in B cells from mev mice. 1994. *Arth. Rheum.* 37(9):S388.

Published as a research associate/technician 1985-1992

1. **Rodriguez A.**, M.R. Liebling, R. Russell, D. Carlberg, and J. Louie. Detection of polymorphic forms of the CD45RA exon in SLE patients and normal controls. Master's Abstracts International, Dec. 1991.
2. Nishio MJ, MR Liebling, **A Rodriguez**, L Siegel, and J Louie. 1990. Identification of Borrelia burgdorferi using interrupted PCR. *Arth. Rheum.* 33:B75.
3. Liebling MR, CF Ware, **A Rodriguez**, and JS Louie. Cloned human T cell lines which specifically suppress anti-DNA production. 1987 *Arth. Rheum.* 30:S88.
4. Keller MA, **A Rodriguez**, DM Reisinger, S Alvarez, and D Stewart. Transfer of tuberculin immunity from mother to infant. 1985. *Clin. Res.* 33:123A.

Presentations

Invited/Oral Presentations

Regional/State

“The TRiCKs behind TRiC in Cancer” FIRE Conference. Keynote speaker at the 11th Annual FIRE Conference at UCF, Feb. 20, 2020.

Fellowship Core Lecture Series - Cell Cycle Regulation. Invited core lecture talk at UF Health Cancer Center, Hematology/Oncology Fellowship Series, May 23, 2019.

“The Future of Cancer Research at UCF” Life@UCF. Invited talk at UCF, July 26, 2019

Speaker for Careers in Oncology. Invited talk at UCF, September 11, 2019

Kickoff to CURE: President’s lunch. Invited talk at the Historic Taproom at Dubsdread, Orlando, FL, September 13, 2019

“Womens Football Academy” invited speaker and interview by Vanessa Echols, WFTV, Bloomingdale’s in The Mall at Millenia, Orlando, FL, Oct. 8, 2018.

“Cancer Immunotherapy – what’s next” Invited core lecture talk at UF Health Cancer Center, Hematology/Oncology Fellowship Series, May 24, 2018.

“Developing the next generation of treatments for cancer”. Invited speaker at the CureBowl Golf Tournament luncheon, Isleworth Gold & Country Club, April 9, 2018.

“Facts about Cancer and Research Updates” Invited speaker at the East Orlando Chamber of Commerce (EOCC) luncheon, Canvas Restaurant, Lake Nona, Sept. 20, 2017

“Therapeutics that target the cell cycle: Successes or Failures?” Invited core lecture talk at UF Health Cancer Center, Hematology/Oncology Fellowship Series, May 23, 2017.

“CCT levels correlate with client proteins in breast cancer” Podium presentation at the 4th Annual Florida Hospital Research Forum, Orlando, FL. May 10, 2017.

“The Dynamic Duo: A Cancer-Targeting Nanoparticle Loaded with a Cytotoxic Peptide as a Treatment for Metastatic Disease” Invited speaker and Session Chair at NanoFlorida 2016, Sept. 26, 2016

“Developing the next generation of treatments for cancer” Invited talk at the Orlando Kiwanis Club, September 7, 2016

“Immunotherapy – what’s next” Invited core lecture talk at UF Health Cancer Center, Hematology/Oncology Fellowship Series, May 5, 2016.

“Chaperonin containing-TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide” 3rd Invited talk at the 3rd Annual Florida Hospital Research Forum, Florida Hospital Creation Conference Center, Orlando, FL, April 21, 2016

“The dynamic duo: A breast cancer-targeting nanoparticle loaded with a cytotoxic peptide as a treatment for metastatic disease.” Invited speaker at the Department of Chemistry & Biochemistry at the Florida State University, Friday, March 25, 2016.

“Tackling Breast Cancer” Science Café Talk, University of Central Florida, Orlando, FL, January 28, 2016.

“Tackling Breast Cancer” Life@UCF Talk, Pegasus Ballroom, Student Union, University of Central Orlando, FL, November 10, 2015.

“Tackling Breast Cancer” UCF Med Talk, City Arts Factory, 29 S. Orange Avenue, Orlando, FL, Oct. 7, 2015

“Cancer Therapeutics: What we’ve learned from animal studies” Invited core lecture talk at UF Health Cancer Center, Hematology/Oncology Fellowship Series, FL, May 2015.

“Killing Cancer Cells with Nano-peptides” Invited speaker at the Morgan Stanley, Health and Wealth Seminar on Feb. 20, 2015 and the Rosalind Club on Feb. 24, 2015, Orlando, FL,

"Killing Cancer Cells with Nano-peptides". Invited speaker at the Florida Breast Cancer Foundation, Education and Advocacy day 2014, Tampa, FL, March 22, 2014.

"Putting the Brakes on Metastatic Breast Cancer". Invited Speaker Orlando Rotary Club, Orlando, FL. Oct. 26, 2013.

"Cell cycling: What we've learned from animal studies" Invited core lecture talk at M. D. Anderson Cancer Center Orlando, FL, May 2013 and 2014.

"Developing Therapeutic Peptides that Target Mitochondria for Cancer Treatment" Invited speaker at Florida Southern College, Lakeland, FL, Feb, 21, 2013.

"Killing Cancer Cells with Nano-peptides". Invited speaker at the Florida Breast Cancer Foundation, Education and Advocacy day 2013, Orlando, FL April 20, 2013

"Cell cycling: What we've learned from animal studies" Invited core lecture talk at M. D. Anderson Cancer Center Orlando, FL, Annual lecture for oncology residents..

"Killing Cells; Killing Cancer." Invited speaker: UCF Luminary Series. Orlando Country Club, Orlando FL. Apr. 29, 2009

"Cell Cycling Through Cdc25A Supports IL-7 Driven Lymphocyte Homeostasis" Invited core lecture talk at M. D. Anderson Cancer Center Orlando, FL, May 29th, 2008.

National/International

"Chaperonin-containing TCP-1 (CCT): A novel molecular target for cancer" Invited lecture. NCI/Frederick, Frederick, MD. May, 2018 (rescheduled due to conflict)

"Chaperonin-containing TCP-1 (CCT): A novel molecular target for cancer." Invited speaker at Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, April 17, 2017.

"The peptide is mightier than the protein: CT20p derived from Bax is a novel therapeutic agent for the treatment of metastatic cancers". Invited speaker at Cedars-Sinai Medical Center, Los Angeles, CA, September 22, 2016.

"Developing the next generation of treatments for cancer" Invited speaker at iNSITE16, Hyatt Regency Orlando, June 7, 2016.

"Tackling Breast Cancer" Invited speaker at the University of South Carolina Medical School, Nov. 6, 2015, Columbia, SC.

"Developing Therapeutic Peptides that Target Mitochondria for Cancer Treatment" Invited speaker at Georgia State University, Atlanta, GA, April 4-5, 2013.

"The Interaction of LCK and the CD4 Co-receptor alters the dose response of T-cells to interleukin-7". Session: Cytokines and Signal Transduction. Cytokines in Infectious Disease, Autoimmune Disorders and Cancer. Chicago, IL, October 4th, 2010.

"IL-7: The Good, the Bad and the Ugly" Invited lecture. NCI-Frederick, Frederick, MD. January 25, 2010.

"Interleukin-7 controls glucose uptake in T-lymphocytes by regulating Hexokinase II expression." Immunology 2009, Annual meeting of AAI, Seattle, WA. May 11, 2009.

"The membrane-binding activity of the apoptotic protein, BAX, is regulated through novel intermolecular interactions". Signal Transduction session. Cytokines in Health and Disease, 15th annual ICS meeting, San Francisco, CA, Oct. 27, 2007.

"Cytokine-driven cell cycling is mediated through Cdc25A". Cytokine and Chemokine Signaling, Experimental Biology 2005, San Diego, CA April 5, 2005.

“Interleukin-7 promotes lymphocyte proliferation through signals transduced by p38 MAPK that regulate the cell cycle activator, Cdc25A” Workshop 1: Signal Transduction. Cytokines in Cancer and Immunity. Joint Meeting of the International Cytokine Society, San Juan, Puerto Rico. October 21-25, 2004.

“G1 Arrest Following IL-3 or IL-7 withdrawal: p38 MAPK phosphorylates Cdc25A leading to its degradation” Seoul National University College of Medicine, Seoul, Korea. November 25th, 2003; International Symposium from Pharmaceutical Resources. Chungbuk National University. Chungbuk, Korea. November 20th, 2003; Seoul Women’s University, Seoul, S Korea, November 18th, 2003.

“Death in the Absence of Trophic Factor Signaling: Lessons Learned from BAX/IL-7 receptor double deficient mice” Guest speaker- Annual meeting Korean Association of Immunobiologists, University of Ulsan, Asan Medical Center, Seoul, Korea. Nov. 21st, 2003; Sahmyook University, Seoul, Korea. Nov. 19th, 2003.

“Death in the Absence of Trophic Factor Signaling: Lessons Learned from Bax/IL-7 Receptor Double Deficient Mice” Session: T cell memory and homeostasis. Immunology 2003, AAI annual meeting. Denver, CO. May 8th, 2003

“Death in the Absence of Trophic Factor Signaling: Lessons Learned from Bax/IL-7 Receptor Double Deficient Mice. Session: TNF Family of Cytokines and Apoptosis” Cytokines and Interferon 2002, Joint Meetings of the International Cytokine Society, Torino, Italy, October 6-10, 2002.

“Loss of Trophic Factor Signaling During Thymocyte Development: On the Pathway to Death through Intracellular Alkalinization and Bax Activation” Session: T Cell Development and Memory. Experimental Biology 2002, AAI Joint Annual Meeting, New Orleans, LA. April 21st, 2002.

“Bax and Mitochondrial Injury: The Multiple Pathways to Death Induced by IL-7 Withdrawal” NIH Research Festival 2001. Mini-Symposium: Mitochondria and Apoptosis, Bethesda, MD. October 4th, 2001.

“Trophic factor withdrawal induces a novel pathway: p38 MAPK activates NHE1 resulting in intracellular alkalinization, an early step in apoptosis” NIH Immunology Interest Group, Bethesda, MD. December 20th, 2000.

“Trophic factor withdrawal induces a novel pathway: p38 MAPK activates NHE1 resulting in intracellular alkalinization. Workshop: Toll and Apoptosis” Third Joint Meeting of the ICS/ISICR, RAI- Amsterdam, The Netherlands. Nov. 9th, 2000.

“Trophic factor withdrawal induces a novel pathway: p38 MAPK activates NHE1 resulting in intracellular alkalinization, an early step in apoptosis” NIH Immunology Retreat, Airlie Center, Virginia. October 23-25, 2000.

“Withdrawal of IL-7 Activates NHE1 causing a rise in pH” 1st Annual Division of Basic Sciences Postdoctoral Fellow Retreat, Hood College, Frederick, MD. 6/12/00.

“IL-7 withdrawal induces a rise in intracellular pH through the NHE causing Bax translocation and a transient mitochondrial hyperpolarization” Minisymposium, Cell Cycle/Proliferation. Immunology 2000, Seattle, WA. May 12, 2000.

“IL-7 withdrawal induces a rapid rise in intracellular pH causing: A) Bax translocation to mitochondria and B) Transient mitochondrial hyperpolarization” Symposium, Apoptosis. Seventh Annual Conference of the ICS, Hilton Head, S.C. Dec. 9, 1999.

“The trophic action of IL-7: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH” Fort Detrick and NCI-FCRDC Spring Research Festival, Frederick, MD. May 13, 1999.

Poster Presentations

Presentations since joining UCF in 2002 (*UCF student and post-doctoral researchers)

1. Martini AC*, RJ Boohaker, D Nierenberg*, **AR Khaled**. Chaperonin-containing TCP1 (CCT) is a novel molecular target for cancer therapy. 2018 Cold Spring Harbor meeting: Mechanisms & Models of Cancer, Aug. 14-18, 2018.
2. **Khaled AR**, Showalter A*, Limaye A*, Bassiouni R, Khaled AS, Oyer J, Igarashi R, and Copik A. Harnessing the immune response for the treatment of cancer by inducing immunogenic cell death through inhibition of a group II chaperonin. Immunology 2017, May 12-16, 2017.
3. Flores O, Niernenberg D, Santra S, Perez JM and **Khaled AR**. Peptide power: A PSMA-targeted CT20 nanoparticle to fight prostate cancer. AACR Annual Meeting, Washington DC, Apr 1-5, 2017.
4. Carr AC*, Khaled AS, Bassiouni R, **Khaled AR**. CT20p as a therapeutic for lung cancer with elevated Chaperonin-Containing TCP1 (CCT) expression levels. AACR Annual Meeting, Washington DC, Apr 1-5, 2017.
5. Vishnubhotla P, Khaled AS, Showalter A*, Limaye A*, Oyer J, Igarashi R, Copik A, **Khaled AR**. A novel therapeutic to enhance the immunogenicity of breast cancer cells. ASCO-SITC meeting, Orlando, FL. Feb. 23, 2017.
6. **Khaled AR**, Khaled AS, Bassiouni R*, Vishnubhotla P. Chaperonin containing-TCP-1 protein level in breast cancer cells predicts therapeutic application of a cytotoxic peptide. AACR Annual Meeting, New Orleans, April 19, 2016.
7. **Khaled AR**, Limaye A*, Bassiouni R*, Showalter A*, Oyer J, Pandey V*, Igarashi R, Altomare DA and Copik AJ. Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy. San Antonio Breast Cancer Symposium, San Antonio TX Dec. 8-12, 2015.
8. Vishnubhotla P, **Khaled AR**, Khaled AS, Perez JM, Bassiouni R*, Flores O* and Nierenberg D*. The dynamic duo: A breast cancer-targeting nanoparticle loaded with a cytotoxic peptide as a treatment for metastatic disease. San Antonio Breast Cancer Symposium, San Antonio TX Dec. 8-12, 2015.
9. Khaled AS, Vishnubhotla P, **Khaled AR** and Bassiouni R*. Cutting the ties that bind: Targeting chaperonin-containing T-complex (CCT) for therapeutic intervention in the treatment of advanced stage breast cancer. San Antonio Breast Cancer Symposium, San Antonio TX Dec. 8-12, 2015.
10. Bassiouni R*, O Flores*, JM Perez, **AR Khaled**. Development of a Cytotoxic Peptide Delivered in Folate-Nanoparticles for the Treatment of Metastatic Breast Cancer. Gordon Conference: Cancer Nanotechnology, Mt. Snow, West Dover, VT June 28-July 3, 2015.
11. Bassiouni R*, A Limaye*, J Oyer, RW Igarashi, O Flores*, JM Perez, A Copik and **AR Khaled**. Use of a Cytotoxic Peptide as an Immunotherapeutic Agent in the Treatment of Metastatic Breast Cancer. AAI, New Orleans, LA May 8-12, 2015.
12. Bassiouni R*, A Limaye*, J Oyer, V Pandey*, RW Igarashi, O Flores, JM Perez, DA Altomare, AJ Copik, and **AR Khaled**. Use of a Cytotoxic Peptide as an Immunotherapeutic Agent

in the Treatment of Metastatic Breast Cancer. NK2015: 15th Meeting of the Society for Natural Immunity. Montebello, Canada May 2-6, 2015.

13. Limaye A*, R Bassiouni*, J Oyer, RW Igarashi, O Flores*, JM Perez, A Copik and **AR Khaled**. Use of a cytotoxic peptide that induces immunogenic cell death to engage innate immunity in the treatment of metastatic breast cancer. AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter. Dec. 1-4, 2014. Orlando, FL.

14. Oyer J, V Pandey*, R Bassiouni*, RW Igarashi, A Zakari, M Solh, **AR Khaled**, DA Altomare, AJ. Copik. Natural killer cells expanded with PM21 particles are cytotoxic toward tumor cells.

AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter. Dec. 14, 2014. Orlando, FL.

15. Vishnubhotla P, MW Lee, R Bassiouni*, AS Khaled, JM Perez and **AR Khaled** Preclinical testing using novel CT20p peptide-nanoparticle combination in breast cancer. 12/10/14 San Antonio Breast Cancer Symposium, San Antonio, TX

16. Vishnubhotla P, MW Lee, R Bassiouni*, AS Khaled, JM Perez and **AR Khaled**. Preclinical testing using novel CT20p peptide-nanoparticle combination in breast cancer. 5/31/13, 2013 ASCO Annual Meeting, Chicago, IL

17. Limaye A., A. Iketani, R. Boohaker, J. Oyer, K. Nemec, M. Solh, A. Copik, and **A.R. Khaled**.

IL-7tv, a Modified Interleukin-7 protein, is a potent agent for immune reconstitution. Oct. 1, 2013, Cytokines 2013, ICIS meeting, San Francisco, CA

18. Boohaker RJ*, C Finch, S Tafur, A Iketani and **AR Khaled**. Structural Insights into the Dynamic Functionality of Bax through Molecular Dynamics Simulations. Wednesday Apr 10, 2013, AACR Annual Meeting 2013 in Washington D.C.

19. Boohaker R*, G Zhang*, K Nemec, **AR Khaled**. Development of a Cytotoxic Peptide base on the C-terminal domain of Bax. AACR, Chicago, FL April, 2012

20. **Khaled AR**, SM Ruppert*, and A Carlson. Bim is a component of the endosomal-lysosomal interface in IL-7 dependent T cells. AAI, San Francisco, CA, May 2011

21. Boohaker R*, KN Nemec and **AR Khaled**. BAX maintains mitochondrial bioenergetics in colon cancer cells. AACR Meeting, Orlando, FL, April 2011.

22. Boohaker R*, KN Nemec and **AR Khaled** Compartmentalization of BCL-2 Family Proteins Mediated by Organelle Lipid Membranes. 54th Biophysical Society Annual Meeting, San Francisco, CA. February 2010

23. Nemec KN, RJ Boohaker*, **AR Khaled**. Biophysical Insights into Bax oligomerization and membrane insertion. 54th Biophysical Society Meeting, San Francisco, CA. Feb. 2010.

24. **Khaled AR**, G Zhang*, S Moore*, R Boohaker*, and AS Khaled. Apoptotic alkalization induced by loss of a growth signal is mediated by phosphorylation of the Na⁺/H⁺ Exchanger isoform 1 at Ser726 and Ser729. Immunology 2009, Seattle, WA May 9, 2009.

25. Chehtane M* and **AR Khaled**. Interleukin-7 controls glucose uptake in T-lymphocytes by regulating Hexokinase II expression. Immunology 2009, Seattle, WA May 9, 2009.

26. Nemec KN, AH Pande, S Qin, SA Tatulian, **AR Khaled**. Bax C-Terminal Peptide - Insights Into Membrane Interactions. Biophysical Society Meeting. Boston, MA. Mar. 3, 2009.

27. Chehtane M* and **AR Khaled**. IL-7 Controls Glucose Uptake in T-Lymphocytes by Regulating Hexokinase II Gene Expression. Cytokines 2008 - October 12-16, 2008 - Montreal CANADA.
28. Kittipatarin C*, WQ Li, SK Durum and **AR Khaled**. Interleukin-7 Expands Memory CD8 T-Cells Through the Activity of Cdc25A. Frontiers in Immunological Memory, Newport Beach, CA. Sept. 25-27, 2008.
29. Kittipatarin C*, WQ Li, K Kim and **AR Khaled**. Generation of CD8 Effector Memory T Cells is Dependent on a Proliferative Signal Mediated by Interleukin-7. GTCbio's 6th Cytokines & Inflammation, Orlando, Florida. January 28-29, 2008.
30. Kittipatarin C*, and **AR Khaled**. Interleukin-7 Drives the Homeostatic Proliferation of T-cells through the Activity of Cdc25A. Cytokines in Health and Disease, 15th annual ICS meeting, San Francisco, CA, Oct. 27, 2007.
31. **Khaled AR**, N. Tschammer*, G Zhang, and T Selby. Structural Transitions that Regulate the Apoptotic Activity of BAX are Dependent on its C-terminal Alpha-9 Helix. Cell Death, SelfRenewal and Cell Cycle in Development. Immunology 2007, 94th annual meeting of AAI, Miami Beach, FL May 20, 2007.
32. Kittipatarin C*, WQ Li, SK Durum and **AR Khaled**. Cytokines Maintain Lymphocyte Homeostasis through Activity of Cdc25A. Session: Cell Cycle Controls II, 46th Annual Meeting of ASCB, San Diego, CA, Dec. 12 2006.
33. Tschammer N*, G Zhang, A Pande, S Qin, S Tatulian, T Selby and **AR Khaled**. Structural Transitions that Regulate the Apoptotic Activity of BAX are Dependent on its C-terminal Helix. Session: Apoptosis II. 46th Annual Meeting of ASCB, San Diego, CA, Dec. 13 2006.
34. **Khaled AR**, C Kittipatarin*, D Bulavin, WQ Li, K Kim, H Young, A Fornace, SK Durum. Cytokine-driven cell cycling is mediated through Cdc25A. Cytokine and Chemokine Signaling, Experimental Biology 2005, San Diego, CA April 5, 2005.
35. N Tschammer*, PX Guo and **AR Khaled**. Use of the bacteriophage phi29 packaging RNA as nanovehicle for targeted delivery of therapeutic RNAs to CD4 T cells. Immunotherapy of Cancer, Exp. Biology 2005, San Diego, CA April 5, 2005.
36. **Khaled A**, A Grenier*, M Alvarez, D Bulavin, WQ Li, K Kim, AJ Fornace and SK Durum. G1 arrest follows loss of cytokine signaling through degradation of Cdc25A, mediated by p38 MAP kinase. G1/S Regulation and Cancer. The Cell Cycle, Chromosome and Cancer, Miami Nature Biotechnology Winter Symposium 2004, Miami, FL. February 2nd, 2004
37. **Khaled AR**, WQ Li, and SK Durum. Death in the absence of cytokine signaling: Lessons learned from BAX/IL-7 receptor double deficient mice. T cell memory and homeostasis. Immunology 2003, AAI Annual meeting, Denver, CO. May 9th, 2003.

Presentations during post-doctoral training from 1997-2002

1. **Khaled AR**, and SK Durum. Loss of Trophic Factor Signaling: On the Pathway to Death through Intracellular Alkalinization and Bax Activation. Gene Expression & Signaling in the Immune System, Cold Spring Harbor, NY. April 24-28, 2002.
2. **Khaled AR**, and SK Durum. Loss of Trophic Factor Signaling During Thymocyte Development: On the Pathway to Death through Intracellular Alkalinization and Bax Activation.

T Cell Development and Memory. Experimental Biology 2002, AAI Joint Annual Meeting, New Orleans, LA. April 21, 2002.

3. **Khaled AR**, CB Thompson, L Fliegel, and SK Durum. Bax and Mitochondrial Injury: The Multiple Pathways to Death Induced by IL-7 Withdrawal. NIH Research Festival 2001, Bethesda, MD. October 3, 2001.

4. **Khaled AR**, and SK Durum. Bax deficiency partially corrects IL-7 receptor deficiency: Rescue of thymocyte differentiation but not expansion. CCR, Post-Doctoral Trainees Assembly Retreat, Hood College, Frederick, MD. June 12, 2001.

5. **Khaled AR**, K Kim, K Muegge, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway: p38 MAPK activates NHE1 causing intracellular alkalinization. Experimental Biology 2001, AAI, Orlando, FL. April 2001.

6. **Khaled AR**, K Muegge, and SK Durum. Trophic factor withdrawal induces novel pathway. NCI CCR Fellows' Symposium, NIH, Bethesda, MD. April 2001.

7. **Khaled AR**, K Kim, K Muegge, C Thompson, L Fliegel, and SK Durum. Trophic factor withdrawal induces novel pathway: p38 MAPK activates NHE1 causing intracellular alkalinization, a novel step in apoptosis. Cell Death and Aging, Miami 2001 Winter Symposium, Miami Beach, FL. February 2001.

8. **Khaled AR**, K Kim, K Muegge, and SK Durum. IL-7 withdrawal induces a rise in intracellular pH through the NHE causing Bax translocation and a transient mitochondrial hyperpolarization. Immunology 2000, AAI, Seattle, WA. May 2000.

9. **Khaled AR**, K Kim, K Muegge, and SK Durum. Withdrawal of IL-7 or IL-3 Activates NHE1 causing a rapid rise in Intracellular pH, resulting in novel mitochondrial effects including the translocation of Bax. Fort Detrick and NCI-FCRDC Spring Research Festival. May 2000.

10. **Khaled AR**, K Kim, R Hofmeister, K Muegge, and S Durum. Withdrawal of IL-7 induces Bax translocation from Cytosol to Mitochondria through a rise in intracellular pH. NIH Research Festival, Bethesda, MD. October 1999.

11. **Khaled AR**, K Kim, K Muegge, and SK Durum. The trophic action of IL-7: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Signal. & Gene Expression in the Immune System, Cold Spring Harbor, NY. June 1999.

12. **Khaled AR**, K Kim, D Reynolds, HA Young, R Youle, K Muegge, and SK Durum. IL-7 Induces Transcription of bcl-2 and bcl-XL and prevents mitochondrial translocation of Bax. Experimental Biology 99, AAI Annual Meeting, Washington, D.C. April 1999

Presentations as a pre-doctoral student from 1992-1997

1. **Khaled A**, E Butfiloski, E Sobel, and J Schiffenbauer. Motheaten viable mice (mev) have defects in NF-kB and IκB protein expression not found in BxSB mice. AAI Joint Annual Meeting, San Francisco, CA. February 1997.

2. **Khaled A**, E Butfiloski, E Sobel, and J Schiffenbauer. Aberrant expression of the NF-kB and IκB proteins in motheaten viable mice has the potential to cause immune dysfunction. ACR, National Meeting, Orlando, FL. October 1996.

3. **Khaled A**, L Soares, E Butfiloski, I Stekman, E Sobel, and J Schiffenbauer. Inhibition of the p50 subunit of NF-kB by antisense oligodeoxy-nucleotides reduces NF-kB expression and immunoglobulin synthesis in murine B cells. AAI Joint Annual Meeting, New Orleans, LA. June 1996.

4. Schiffenbauer J, **A Rodriguez**, and E Butfiloski. Aberrant expression of NF-kB in B cells from mev mice. Graduate Student Forum, University of Florida, Gainesville, FL. 3/1995.

Presentations as a research associate/technician 1985-1992

Rodriguez A, MR Liebling, R Russell, D Carlberg, and J Louie. Detection of polymorphic forms of the CD45RA exon in SLE patients and normal controls. ASM, San Diego, CA. 1991.

Service

University of Central Florida

University Service

Member, Institutional Animal Care and Use Committee (IACUC).....2015-present
Member, UCF Graduate Council2016-2017
COM representative, Faculty Senate Steering committee.....2015-2016
Chair, UCF Graduate Council2014-2016
Chair, UCF Graduate Policy Committee2014-2016
Senator, UCF Faculty Senate.....2014-2016
Member, Taskforce, University Tuition Waivers.....2012-2014
Member, Search Committee for Dean of the College of Graduate Studies.....2012-2013
Chair, Budget and Administration Committee.....2009-2010
Member, Graduate Council, Awards and Appeals Committee.....2009-2011
Senator, UCF Faculty Senate2008-2010
Member, University Travel Committee.....2006-2008
Member, IACUC.....2005-2009

College of Medicine (COM) Service

President, COM faculty council.....2020-2021
Vice-president, COM faculty council.....2019-2020
Member, COM Research strategic planning committee.....2019-present
Chair, Search committee for physician-scientist in oncology.....2018-2019
Member, Research sub-committee for UCF Lake Nona Cancer Center.....2018-present
Member, Research Council.....2017-present
Member, Search Committee for Director of ID Center of Excellence.....2017-2018
Member, Education Taskforce for Strategic Planning.....2014-2015
Member, Institutional Efficiency Committee.....2015
Member, Faculty Council: Faculty Advocate Committee.....2014-2020
Member, Five-Year Evaluation Committee for Dean of COM.....2013-2014
Member, Search Committee for Associate Dean for Research.....2011-2012
Past President, COM Faculty Council.....2012-2013
Member, Enterprise Committee (COM Leadership).....2010-2013
President, COM Faculty Council.....2010-2012
Member, COM curriculum development/planning committees.....2007-2010
Member, Basic Science Faculty Search Committee.....2007-2008

Unit (Burnett School of Biomedical Sciences - BSBS) Service

<i>Chair</i> , Search Committee for Genomic/Bioinformatics Cluster Faculty.....	2017-2018
<i>Chair</i> , PhD program Executive Committee.....	2017-present
<i>Member</i> , Search Committee: Cancer Faculty Search.....	2015-2016
<i>Chair</i> , Ph.D. Program Admissions Committee	2015
<i>Chair</i> , Search Committee: Immunology/Inflammation Faculty Search	2014-2015
<i>Member</i> , Search Committee for Director of BSBS.....	2013-2014
<i>Member</i> , Undergraduate Curriculum committee.....	2013-2016
<i>Member</i> , Five year Evaluation Committee for BSBS Director.....	2011-2012
<i>Chair</i> , PhD program Graduate Curriculum Committee	2009-2011
<i>Member</i> , Research Faculty Promotion and Tenure Guidelines Committee.....	2009-2012
<i>Member</i> , Teaching Faculty Promotion Guidelines Committee.....	2009-2012
<i>Member</i> , MS/MBA and MS Biotechnology Programs Graduate Committee.....	2008-2012
<i>Member</i> , Ph.D. Program Admissions Committee.....	2006-2016
<i>Member</i> , Department/College Assessment Institutional Effectiveness.....	2005-2006
<i>Member</i> , BSBS Honors Committee.....	2005-2010
<i>Organizer</i> , BSBS Faculty Seminar Series.....	2003-2008

External Service

Board Membership

Secretary and Board Director Florida Breast Cancer Foundatio.....2016-present

Scientific Board Memberships

Chair, Florida Breast Cancer Foundation.....2016-present

Advisory Committee Memberships

Member, Advisory Council, Valencia College Biotechnology Program.....2017-present

Vice-president, Executive Committee of the UCF Chapter of the NAI.....2017-2018

Editorial Board Membership

Editor, Newsletter for ICIS (International Cytokine and Interferon Society).....2012-2017

Member, Editorial Board, *Cytokine*.....2010-present

Member, Editorial Board, *Signals*.....2018-present

Review of Grant Proposals

Permanent member, NIH, Cancer Prevention Study Section (CPSS).....2018-present

Panel member, NCI-I subcommittee, "Transition to Independence".....2017-present

Panel member, NIH AREA R15 SEP Grants Study Section 2016-present || *Ad hoc member*, NASA EPSCoR on-line Review of Grants..... | 2015-2016 |
Panel member, NIH Immunology F07-T20 & IMM-T81 Study Section.....	2014-present
Panel member, Cancer Health Disparities and Diversity in Basic Cancer Research Study Section for NCI.....	2010-2016
Ad hoc member, SBIR Nanoscience Technology Study Section for NCI.....	2010
Permanent member, NCI subcommittee F: Manpower and Training.....	2008-2013

Review of Scientific Papers

Manuscripts reviewed for *Advanced Materials, Communications Biology, Biotechnology Letters, Cytokine, Science Translational, Clinical Cancer Research, Oncology Reports, Oncology Letters, Oncotarget, Cancer Research, Molecular Cancer Therapeutics, Biomarker Research, PLoS One, Molecular Pharmaceutics, Scientific Reports, Journal of Immunology, Journal of Leukocyte Biology, Blood, Biomed Res. International, Immunology, American Journal Physiol., Biomedical and Environmental Sciences, and Cellular Physiology and Biochemistry*

Professional Society Memberships:

- National Academy of Inventors (NAI) (UCF Chapter).....2016-Present
- American Association of Cancer Researchers (AACR)2010-Present
- International Cytokine and Interferon Society (ICS), full member.....2004-Present
- American Association of Immunologists (AAI), full member.....2003-Present

Professional Development Activities

- Fellow*, Executive Leadership in Academic Medicine (ELAM).....2018-2019
- Participant*, AAMC Mid-Career Minority Faculty Development Seminar.....Sept. 17-19, 2015
- Participant*, AAMC Mid-Career Women Faculty Development Seminar.....Dec. 1-4, 2012
- Participant*, AAMC GREAT/GRAND Conference.....Sept. 20-22, 2012

Service Award

University of Central Florida

- Outstanding Service Award, COM Faculty and Student Awards.....2015